Do analysts recommend LIAN or MGX?

Metagenomi has a consensus target price of $9.00, suggesting a potential upside of 614.29%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has preferable valuation & earnings, LIAN or MGX?

Metagenomi has higher revenue and earnings than LianBio. Metagenomi is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Metagenomi $25.21M 1.88 -$87.87M -$2.30 N/A

Is LIAN or MGX more profitable?

LianBio has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. LianBio's return on equity of -33.17% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Metagenomi -384.61% -51.23% -36.62%

Do analysts rate LIAN or ACTU?

Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 1,051.32%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings and valuation, LIAN or ACTU?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is LIAN or ACTU more profitable?

LianBio's return on equity of -33.17% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Actuate Therapeutics N/A -430.93% -180.86%

Do analysts prefer LIAN or APLM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, LIAN or APLM?

Apollomics has higher revenue and earnings than LianBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Apollomics $8.50M 5.06 -$10.94M N/A N/A

Is LIAN or APLM more profitable?

Apollomics' return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Apollomics N/A N/A N/A

Do analysts prefer ELUT or LIAN?

Elutia currently has a consensus price target of $6.00, indicating a potential upside of 543.78%. Given Elutia's stronger consensus rating and higher possible upside, equities analysts plainly believe Elutia is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, ELUT or LIAN?

Elutia has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elutia $12.46M 3.20 $53.38M $0.86 1.08 LianBio N/A N/A -$110.29M -$0.81 N/A

Is ELUT or LIAN more profitable?

Elutia has a net margin of 312.09% compared to LianBio's net margin of 0.00%. Elutia's return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 312.09% N/A -53.97% LianBio N/A -33.17% -30.19%

LianBio (LIAN) Competitors

$0.12 0.00 (0.00%)

As of 07/2/2026

Compare

LIAN vs. MGX, ACTU, NBRV, APLM, and ELUT

Should you buy LianBio stock or one of its competitors? MarketBeat compares LianBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LianBio include Metagenomi (MGX), Actuate Therapeutics (ACTU), Nabriva Therapeutics (NBRV), Apollomics (APLM), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry.

How does LianBio compare to Metagenomi?

LianBio (NASDAQ:LIAN) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

74.8% of LianBio shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Metagenomi has a consensus target price of $9.00, suggesting a potential upside of 614.29%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, LianBio's average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Metagenomi	Neutral

LianBio has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. LianBio's return on equity of -33.17% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Metagenomi	-384.61%	-51.23%	-36.62%

Metagenomi has higher revenue and earnings than LianBio. Metagenomi is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Metagenomi	$25.21M	1.88	-$87.87M	-$2.30	N/A

Summary

Metagenomi beats LianBio on 8 of the 14 factors compared between the two stocks.

How does LianBio compare to Actuate Therapeutics?

LianBio (NASDAQ:LIAN) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

74.8% of LianBio shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, LianBio's average media sentiment score of 0.00 equaled Actuate Therapeutics'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Actuate Therapeutics	Neutral

Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 1,051.32%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

LianBio's return on equity of -33.17% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Actuate Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Summary

Actuate Therapeutics beats LianBio on 6 of the 11 factors compared between the two stocks.

How does LianBio compare to Nabriva Therapeutics?

LianBio (NASDAQ:LIAN) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Nabriva Therapeutics has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

In the previous week, LianBio's average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Nabriva Therapeutics	Neutral

LianBio has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. LianBio's return on equity of -33.17% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

LianBio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

74.8% of LianBio shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

LianBio beats Nabriva Therapeutics on 6 of the 10 factors compared between the two stocks.

How does LianBio compare to Apollomics?

LianBio (NASDAQ:LIAN) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Apollomics had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for LianBio. Apollomics' average media sentiment score of 0.59 beat LianBio's score of 0.00 indicating that Apollomics is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Apollomics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics' return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Apollomics	N/A	N/A	N/A

74.8% of LianBio shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Apollomics has higher revenue and earnings than LianBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A

Summary

Apollomics beats LianBio on 8 of the 10 factors compared between the two stocks.

How does LianBio compare to Elutia?

Elutia (NASDAQ:ELUT) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Elutia has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.46M	3.20	$53.38M	$0.86	1.08
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

In the previous week, Elutia's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company	Overall Sentiment
Elutia	Neutral
LianBio	Neutral

Elutia has a net margin of 312.09% compared to LianBio's net margin of 0.00%. Elutia's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
LianBio	N/A	-33.17%	-30.19%

74.0% of Elutia shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Elutia has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Elutia currently has a consensus price target of $6.00, indicating a potential upside of 543.78%. Given Elutia's stronger consensus rating and higher possible upside, equities analysts plainly believe Elutia is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Elutia beats LianBio on 11 of the 13 factors compared between the two stocks.

Get LianBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIAN vs. The Competition

Export

Metric	LianBio	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.43M	$431.50M	$7.16B	$12.48B
Dividend Yield	N/A	3.88%	2.66%	6.52%
P/E Ratio	-0.14	3.09	28.02	24.70
Price / Sales	N/A	6,669.11	540.37	99.49
Price / Cash	N/A	13.13	49.26	57.09
Price / Book	0.04	88.67	10.96	6.46
Net Income	-$110.29M	-$96.07M	$3.57B	$337.01M
7 Day Performance	-28.08%	0.17%	2.12%	1.69%
1 Month Performance	-17.27%	2.10%	5.25%	3.81%
1 Year Performance	-73.46%	68.02%	33.29%	23.90%

LianBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIAN LianBio	N/A	$0.12 flat	N/A	-73.5%	$12.43M	N/A	N/A	110
MGX Metagenomi	2.3722 of 5 stars	$1.20 -3.2%	$9.00 +650.0%	-23.8%	$46.68M	$25.21M	N/A	236
ACTU Actuate Therapeutics	1.8006 of 5 stars	$1.95 +1.0%	$17.50 +797.4%	-76.7%	$46.18M	N/A	N/A	10	Positive News
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70	Gap Up
APLM Apollomics	0.7489 of 5 stars	$20.50 +2.0%	N/A	+200.7%	$44.12M	$8.50M	N/A	45

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIAN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LianBio (LIAN) Competitors